Anzeige
Mehr »
Login
Sonntag, 14.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Sonderausgabe: Kommt die große Meldung schon zu Wochenbeginn?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T | ISIN: JP3475350009 | Ticker-Symbol: D4S
Tradegate
12.04.24
12:54 Uhr
27,980 Euro
+0,070
+0,25 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
27,88028,33013.04.
27,71028,14012.04.

Aktuelle News zur DAIICHI SANKYO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med706
MoAstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod754
MoAstraZeneca/Daiichi Sankyo's Enhertu granted FDA accelerated approval for solid tumours392
MoFDA approves Daiichi Sankyo-AstraZeneca's Enhertu for solid tumours60
06.04.Daiichi Sankyo: ENHERTU Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors1.561Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca's ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications...
► Artikel lesen
06.04.FDA Approves AstraZeneca And Daiichi Sankyo's Enhertu For Solid Tumors Treatment2.039LONDON (dpa-AFX) - The U.S. Food and Drug Administration approved AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult...
► Artikel lesen
02.04.FDA accepts Daiichi Sankyo-AstraZeneca's breast cancer therapy for review4
02.04.AZ, Daiichi Sankyo file Dato-DXd for second indication1
28.03.Dividendenbekanntmachungen (28.03.2024)11.593 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ACOM CO LTD  JP3108600002  6 JPY  0,0366 EUR  ADVANEX INC  JP3213400009  20 JPY  0,1222 EUR  AICA KOGYO CO LTD  JP3100800006  59 JPY  0...
► Artikel lesen
22.03.Daiichi Sankyo: CHMP gibt positive Stellungnahmen für Bempedosäure und die Bempedosäure/Ezetimib-Kombinationstablette zur Behandlung von Hypercholesterinämie und zur signifikanten Verringerung kardiovaskulärer Ereignisse ab877Die positiven Stellungnahmen des CHMP beruhen auf den Analysen der Phase-3-Studie CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes. 1 ...
► Artikel lesen
22.03.Daiichi Sankyo: CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular events434Positive CHMP opinions are based on the analyses of the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial.1 European...
► Artikel lesen
13.03.Daiichi Sankyo's Vanflyta approved by MHRA to treat acute myeloid leukaemia3
12.03.MHRA authorises Daiichi Sankyo quizartinib for AML for marketing3
07.03.AstraZeneca/Daiichi Sankyo's Enhertu not recommended by NICE for advanced breast cancer7
07.03.UK NICE rejects Daiichi Sankyo's Enhertu for breast cancer5
04.03.EMA awards double validation for Daiichi Sankyo and AstraZeneca's cancer ADC5
04.03.EMA validates Daiichi Sankyo-AstraZeneca's cancer therapy applications3
04.03.AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment10
04.03.Daiichi Sankyo: Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer194Parallel applications based on TROPION-Lung01 and TROPION-Breast01 phase 3 trial results demonstrating Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan significantly improved progression-free...
► Artikel lesen
21.02.Daiichi Sankyo Invests €1 Billion in Munich Site6
Seite:  Weiter >>
98 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1